ClinicalTrials.gg
Drug

Molnupiravir clinical trials

Also written MK-4482 and EIDD-2801.

studies test it
23
open now
7
in phase 3
8
first study started
2020

How each study uses molnupiravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the molnupiravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Molnupiravir
18
LAGEVRIO
3
MOV
2
Molnupiravir 200 mg
2
Molnupiravir 400 mg
2

Development codes

MK-4482
9
EIDD-2801
4
JCBC00101
1

Studies by the year they started

23 studies that test it; most in 2020 (7)

Studies that test molnupiravir, by start year
YearStudies
20207
20214
20226
20233
20242
20261

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
11
Phase 3
8
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 9

Merck Sharp & Dohme LLC (9) · University of Oxford (4) · Ridgeback Biotherapeutics, LP (3) · University of Witwatersrand, South Africa (1) · Geropharm (1) · Valenta Pharm JSC (1) · Promomed, LLC (1) · Oxford University Clinical Research Unit, Vietnam (1)

Often tested with

Tested in the same studies.

Favipiravir (4) · Nirmatrelvir and ritonavir drug combination (3) · Remdesivir (2) · Nitazoxanide (2) · Hydroxychloroquine (2) · Sotrovimab (2) · Baloxavir (2) · Oseltamivir (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test molnupiravir.

Studies

Open first, then newest update. How each study uses molnupiravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test molnupiravir →

Given beside what is tested · 1 — molnupiravir is usual care or a partner of the new treatment

Codes

What other systems call molnupiravir · ClinicalTrials.gg INT001256

  • MeSH (NLM) C000656703molnupiravirConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) YA84KI1VEWMOLNUPIRAVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 2587901One source FDA
  • Wikidata Q96376832molnupiravirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C172633MolnupiravirOne source FDA
  • DrugBank DB15661One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.